Scabies Market

Market Overview:

The 7 major scabies markets reached a value of USD 215.2 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 382.1 Million by 2035, exhibiting a growth rate (CAGR) of 5.39% during 2025-2035.

The scabies market has been comprehensively analyzed in IMARC's new report titled "Scabies Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Scabies is an infectious skin infestation brought about by the Sarcoptes scabiei mite, which burrows into the skin to cause severe itching and rashes. This parasitic infection is transmitted through extended skin contact and can infect people of any age with more incidence in densely populated living areas and institutions. The illness mostly presents as itching that persists, particularly at night, with lesions on the skin in the form of burrows, papules, and crusted sores, which, if not treated, can result in secondary bacterial infections. Scabies is mostly diagnosed clinically from the symptoms and physical examination. In uncertain situations, though, dermoscopy, microscopic detection of eggs or mites by skin scrapings, and newer imaging modalities like reflectance confocal microscopy can be used for verification. Topical scabicides like permethrin and oral antiparasitic drugs like ivermectin are used in the treatment, and this is sometimes accompanied by decontamination of clothing and bedding to avoid reinfestation.

The increasing incidence of scabies, especially in the tropics and resource-poor settings, is one of the main drivers for market expansion. Scabies is very infectious and can easily spread in close-contact human settings, including nursing homes, refugee camps, prisons, and childcare centers. The high incidence in these settings is generating a continuous need for good treatments. Secondarily, secondary bacterial infections such as impetigo, cellulitis, and post-streptococcal glomerulonephritis are also key concerns, driving clinicians to act quickly on diagnosis and treatment. The industry is also being fueled by improved therapeutic solutions, including combination therapy and new drug formulation, that drive efficacy and diminish resistance. Oral ivermectin is taking precedence for simplicity of use and efficacy in acute cases, as newer topical solutions are under consideration to enhance compliance among patients. In addition, public health activities and government-funded programs are fostering awareness and making treatment accessible at high-prevalence sites. Advances in diagnostics, including artificial intelligence-powered imaging and quick molecular diagnostics, are enhancing early identification, pushing further growth in the market. These factors combined make up an increasing international market for the treatment of scabies.

IMARC Group's new report provides an exhaustive analysis of the scabies market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the scabies market in any manner.

Key Highlights:

• Scabies affects over 200 million people globally at any time, with annual cases exceeding 400 million, highlighting its widespread burden.
• Untreated scabies can lead to bacterial infections like impetigo, increasing risks of sepsis, kidney disease, and rheumatic heart disease, worsening overall health outcomes.
• Severe itching and skin lesions cause sleep disturbances, social stigma, and absenteeism, negatively affecting education, work productivity, and mental well-being.
• Scabies disproportionately affects overcrowded and impoverished communities, particularly in refugee camps, island regions, and low-income urban areas, exacerbating healthcare challenges.
• Scabies outbreaks place financial strain on healthcare systems, with high treatment costs in both resource-limited settings and developed countries managing widespread infestations.

Drugs:

Natroba (Spinosad topical) is a prescription treatment for scabies, offering a potent pediculicidal effect by targeting the nervous system of mites, leading to paralysis and death. Applied topically, it provides a single-use alternative to traditional scabicides, reducing the need for multiple applications. Its efficacy and ease of use make it a valuable option for patients with refractory or severe scabies infestations.

Ivermectin, developed by Merck & Co., is an oral antiparasitic agent widely used for scabies, particularly in refractory or crusted cases. It disrupts neurotransmission in mites, leading to paralysis and death. Often recommended for patients unresponsive to topical therapies, ivermectin offers systemic efficacy, making it a critical option for managing widespread or institutional outbreaks of scabies with improved patient compliance.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the scabies market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the scabies market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current scabies marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the scabies market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the scabies market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the scabies market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035​) of scabies across the seven major markets?
• What is the number of prevalent cases (2019-2035​) of scabies by age across the seven major markets?
• What is the number of prevalent cases (2019-2035​) of scabies by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with scabies across the seven major markets?
• What is the size of the scabies patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of scabies?
• What will be the growth rate of patients across the seven major markets?

Scabies: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for scabies drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the scabies market?
• What are the key regulatory events related to the scabies market?
• What is the structure of clinical trial landscape by status related to the scabies market?
• What is the structure of clinical trial landscape by phase related to the scabies market?
• What is the structure of clinical trial landscape by route of administration related to the scabies market?